glp 1 bipolar disorder Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in disorder: a narrative review of preclinical and clinical evidence GLP-1s: Real Stories From People

Doctors say timing is different for each person

The retatrutide question Some Mexico pharmacy visitors ask about retatrutide, the next-generation triple-agonist that targets GLP-1, GIP, and glucagon receptors simultaneously

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial

Future research must prioritize the inclusion of sex as a biological variable, explore differential receptor expression and function, and validate the safety and efficacy of dual agonist strategies in humans

Sermorelin vs